Health ❯ Pharmaceuticals ❯ Drug Development

Clinical Trials

Monoclonal Antibodies Obesity Treatments Lenacapavir FDA Approval Efficacy Studies Semaglutide Regulatory Approval Phase 3 Trials Multiple Sclerosis Retatrutide

Xenon Files FDA New Drug Application for Azetukalner After Pause in Depression Trials

The submission advances a potential first epilepsy approval while unresolved neuropsychiatric signals could force dosing changes or further study.

Novartis Moves to File Oral MS Drug After Phase‑3 Win as Separate CAR‑T Trials Are Paused

Fulcrum Agrees to Merge With Slate Medicines, Plans Nasdaq Relaunch as SLTE

Lilly Sues Six U.S. Firms Over Black‑Market Sales of Experimental Drug Retatrutide

FDA Panel Rejects Deramiocel Cardiac Claim After Lancet Publishes HOPE‑3 Results

Oral Antiviral Candidate Stops Measles-Like Virus Transmission in Ferret Study

Sanofi Names Paulo Fontoura Global Head of R&D Pharma

FulcrumSec Claims 1.3TB Theft From Novo Nordisk

Neumora Halts Navacaprant After Phase 3 KOASTAL Failures

FDA Places Full Clinical Hold on Aardvark’s ARD-101 Prader–Willi Trials

FDA Chief Makary Faces Intensifying Pressure as Vape Approvals and Staff Shake-Up Fuel Scrutiny

Analysts Lift Eli Lilly Targets After Blowout Quarter and Foundayo Debut

Medicus Pharma Reports Long-Acting Hormone Control in Phase 1 Teverelix Data

UniQure Investors Face Lead‑Plaintiff Deadline in Securities Fraud Case

Ultragenyx Hit With Securities Class Action Over Failed Phase III Trials

Cancer Study Maps Brain Metastasis Switch and Identifies Ibudilast as a Repurposing Candidate

Gilead to Buy Ouro Medicines for $1.675 Billion Upfront to Advance Autoimmune T‑Cell Engager

AIM ImmunoTech Secures Final Japan Patent for Ampligen Checkpoint-Inhibitor Cancer Therapy

EMA Backs Single-Dose Acoziborole for Gambiense Sleeping Sickness Outside EU

Japan Panel Clears iPS Cell Therapies for Heart Failure and Parkinson’s